Literature DB >> 17679671

Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.

S Worgall1, M V Kekatpure, L Heier, D Ballon, J P Dyke, D Shungu, X Mao, B Kosofsky, M G Kaplitt, M M Souweidane, D Sondhi, N R Hackett, C Hollmann, R G Crystal.   

Abstract

BACKGROUND: Late infantile neuronal ceroid lipofuscinosis (LINCL) is associated with progressive degeneration of the brain and retina starting in early childhood.
METHODS: Thirty-two individual neurologic, ophthalmologic, and CNS imaging (MRI and MRS) assessments of 18 children with LINCL were analyzed. Disease severity was followed by two rating scales, one previously established but modified to solely assess the brain and exclude the retinal disease (modified Hamburg LINCL scale), and a newly developed scale, with expanded evaluation of the CNS impairment (Weill Cornell LINCL scale).
RESULTS: For the 18 children, the Weill Cornell scale yielded a closer correlation with both age and time since initial clinical manifestation of the disease than did the modified Hamburg scale. There were no significant differences as a function of age or time since initial manifestation of the disease in the rating scales among the most frequent CLN2 mutations (G3556C, 56% of all alleles or C3670T, 22% of all alleles). Measurements of cortical MRS N-acetyl-aspartate content, MRI ventricular, gray matter and white matter volume, and cortical apparent diffusion coefficient correlated to a variable degree with the age of the children and the time since initial clinical manifestation of the disease. All imaging measurements correlated better with the Weill Cornell CNS scale compared to the modified Hamburg LINCL scale.
CONCLUSION: The data suggest that the Weill Cornell late infantile neuronal ceroid lipofuscinosis (LINCL) scale, together with several of the MRI measurements, may be useful in the assessment of severity and progression of LINCL and for the evaluation of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17679671     DOI: 10.1212/01.wnl.0000267885.47092.40

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

1.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

Review 2.  Lysosomal storage disease overview.

Authors:  Angela Sun
Journal:  Ann Transl Med       Date:  2018-12

3.  When ethics constrains clinical research: trial design of control arms in "greater than minimal risk" pediatric trials.

Authors:  Inmaculada de Melo-Martín; Dolan Sondhi; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2011-05-19       Impact factor: 5.695

Review 4.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

Review 5.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

6.  Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  Erika F Augustine; Heather R Adams; Christopher A Beck; Amy Vierhile; Jennifer Kwon; Paul G Rothberg; Frederick Marshall; Robert Block; James Dolan; Jonathan W Mink
Journal:  Dev Med Child Neurol       Date:  2014-11-11       Impact factor: 5.449

7.  Subdural fluid collections in patients with infantile neuronal ceroid lipofuscinosis.

Authors:  Sondra W Levin; Eva H Baker; Andrea Gropman; Zenaide Quezado; Ning Miao; Zhongjian Zhang; Alice Jollands; Matteo Di Capua; Rafael Caruso; Anil B Mukherjee
Journal:  Arch Neurol       Date:  2009-12

8.  Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging.

Authors:  J P Dyke; D Sondhi; H U Voss; D C Shungu; X Mao; K Yohay; S Worgall; N R Hackett; C Hollmann; M E Yeotsas; A L Jeong; B Van de Graaf; I Cao; S M Kaminsky; L A Heier; K D Rudser; M M Souweidane; M G Kaplitt; B Kosofsky; R G Crystal; D Ballon
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

9.  Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.

Authors:  Dolan Sondhi; Daniel A Peterson; Andrew M Edelstein; Katrina del Fierro; Neil R Hackett; Ronald G Crystal
Journal:  Exp Neurol       Date:  2008-04-30       Impact factor: 5.330

Review 10.  Lysosomal storage diseases--the horizon expands.

Authors:  Rose-Mary Naaman Boustany
Journal:  Nat Rev Neurol       Date:  2013-08-13       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.